Evogene 

ILA906.3
29
+ILA5.1+0.57% Tuesday 15:24

统计数据

当日最高
942
当日最低
890.1
52周最高
3,700
52周最低
883.8
成交量
58,774
平均成交量
11,240
市值
104.98M
市盈率
-
股息收益率
-
股息
-

即将到来

收益

13Nov预期
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
Q2 2024
下一个
-1.25
-0.83
-0.42
0
预期每股收益
-1.01
实际每股收益
N/A

人们还关注

此列表基于关注EVGN.TA的Stock Events用户的观察列表。这不是投资建议。

竞争者

这个列表是基于最近市场事件的分析。这不是投资建议。
Editas Medicine
EDIT
市值308.46M
Editas Medicine 在基因组编辑领域开展业务,直接与 Evogene 的计算生物学方法竞争,以开发改良植物特性和医疗解决方案。
CRISPR Therapeutics
CRSP
市值4.06B
CRISPR Therapeutics参与基因编辑,与Evogene在基因工程解决方案的开发中成为竞争对手,二者在类似的生物技术领域中运作。
Intellia Therapeutics
NTLA
市值2.28B
Intellia Therapeutics是CRISPR/Cas9基因组编辑技术的另一家重要参与者,与Evogene的基因组分析和工程竞争。
Beam Therapeutics
BEAM
市值2.2B
Beam Therapeutics在精确编辑DNA方面与Evogene竞争,这对于农业和治疗的进展至关重要。
Corteva
CTVA
市值39.67B
Corteva Agriscience 在农业领域运营,专注于种子技术和作物保护,这也是 Evogene 旨在创新的领域。
Bionano Genomics
BNGO
市值42.14M
Bionano Genomics提供基因组分析工具,与Evogene的计算基因组方法竞争,以了解复杂的生物系统。
Pacific Biosciences of California
PACB
市值373.36M
Pacific Biosciences提供长读取测序技术,这对于Evogene进行的基因组研究和开发工作至关重要。
Twist Bioscience
TWST
市值2.53B
Twist Bioscience 在合成生物学领域运营,制造与 Evogene 的基因组和分子研究直接竞争的 DNA 合成产品。
Adaptive Biotechnologies
ADPT
市值693.12M
Adaptive Biotechnologies参与了基因免疫测序领域,与Evogene利用计算生物学来理解和操纵生物系统的方法相竞争。

关于

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in multiple life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The CPB platform, incorporating a deep understanding of biology leveraged through big data and artificial intelligence, designed to computationally discover and uniquely guide the development of life-science products based on microbes, small molecules, and genetic elements. The company operates through three segments: Agriculture, Human Health, and Industrial Applications. The Agriculture segment develops seed traits, ag-chemical products, and ag-biological products to enhance plant performance. Its products focus on various crops, such as corn, soybean, wheat, rice, and cotton. The Industrial Applications segment develops enhanced castor bean seeds to serve as a feedstock source for other industrial uses. The Human Health segment discovers and develops human microbiome-based therapeutics for the treatment of immuno-oncology, GI related disorders, and antimicrobial resistance organisms. The company also provides medical cannabis products. It operates in the United States, Israel, Brazil, and internationally. The company has strategic collaborations and licensing agreements with agricultural companies, such as BASF SE, Corteva, and Bayer; and through its subsidiary, Canonic Ltd., has a collaboration agreement with Cannbit Ltd. for the development of novel medical cannabis products. Evogene Ltd. was founded in 1999 and is headquartered in Rehovot, Israel.
Show more...
首席执行官
Mr. Ofer Haviv CPA
员工
133
国家
Israel
ISIN
IL0011050551

上市公司